Clinical Trials Directory

Trials / Completed

CompletedNCT06735222

Bioavailability of Hydroxytyrosol in Humans Co-administered With EPA

Hydroxytyrosol Bioavailability in Humans: A Comparative Study of Three EPA-Enriched Formulations

Status
Completed
Phase
N/A
Study type
Interventional
Enrollment
12 (actual)
Sponsor
National Research Council, Spain · Other Government
Sex
All
Age
18 Years – 45 Years
Healthy volunteers
Accepted

Summary

The primary objective of this study is to evaluate the optimal formulation of a natural nutraceutical whose daily consumption at nutritional doses may confer benefits for cardiovascular health. This nutraceutical combines an omega-3 fatty acid (eicosapentaenoic acid, EPA) with hydroxytyrosol (a potent antioxidant found in olives and extra virgin olive oil). The study will allow to compare how and to what extent hydroxytyrosol is absorbed when co-administered the omega-3 fatty acid in capsules across three different formulations.

Detailed description

12 healthy male and female participants will consume various formulations corresponding to three nutraceuticals developed: hydroxytyrosol acetate (HT-Ac), hydroxytyrosol eicosapentanoate (HT-EPA), and hydroxytyrosol extract (Oleacore®) with EPA. One week prior to the intervention, participants will be instructed to refrain from consuming extra virgin olive oil or olives as the primary dietary sources of hydroxytyrosol (wash-out phase). Since three types of nutraceuticals will be evaluated, the study will take place over three separate days, with one week between each intervention. On each intervention day, following an overnight fast, volunteers will randomly consume one of the nutraceuticals. A polyphenol-free diet will be provided during the 24 hours after the nutraceutical intake. Blood samples will be collected right before the nutracetical intake at 0.5, 1, 1.5, 2, 3, 4, 6, 8, 10 and 24 hours post-consumption. Urine samples will also be collected in 24-hour collection containers containing 0.5 g of ascorbic acid, at the following intervals: -2 to 0 hours (baseline), 0-3 hours, 3-6 hours, 6-10 hours, and 10-24 hours. All of these samples will be stored at -80ºC until analysis.

Conditions

Interventions

TypeNameDescription
DIETARY_SUPPLEMENTHydroxytyrosol acetate (HT-Ac)Hydroxytyrosol acetate (15 mg) orally co-administered with 2 g EPA
DIETARY_SUPPLEMENTHydroxytyrosol eicosapentanoate (HT-EPA)Oral intake of hydroxytyrosol eicosapentanoate (15 mg) solubilized in an EPA-enriched oil matrix.
DIETARY_SUPPLEMENTOleacore®Oleacore® (containing 15 mg of hydroxytyrosol) orally co-administered with 2 g EPA

Timeline

Start date
2024-11-18
Primary completion
2024-12-04
Completion
2024-12-04
First posted
2024-12-16
Last updated
2025-04-11

Locations

1 site across 1 country: Spain

Source: ClinicalTrials.gov record NCT06735222. Inclusion in this directory is not an endorsement.